BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...atrophy and helped preserve neuromuscular junctions. For further support, Hayden pointed to the studies of Nuedexta...
...with ALS and multiple sclerosis. Avanir was acquired by Otsuka Holdings Co. Ltd.(JASDAQ:4578) in 2015. Nuedexta...
BioCentury | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

...have offered kickbacks and issued false and misleading marketing relating to pseudobulbar affect drug Nuedexta dextromethorphan/quinidine. Hongjiang...
BioCentury | Aug 17, 2015
Clinical News

Nuedexta dextromethorphan/quinidine: Phase IV data

...Phase IV PRISM II trial in 367 patients with PBA showed that twice-daily 20/10 mg Nuedexta...
...Nuedexta in the U.S. to treat PBA. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Nuedexta...
...PBA. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Nuedexta dextromethorphan/quinidine ( AVP-923 ) (formerly Neurodex...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...acute lymphoblastic leukemia (ALL) EU (approved in U.S. 2012) $34.4 Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) Nuedexta dextromethorphan/quinidine...
BioCentury | Dec 15, 2014
Finance

Avanir Chronicles

...which said the deal will accelerate its expansion in neurology, gets pseudobulbar affect drug Nuedexta dextromethorphan/quinidine...
...approvable letter for an NDA for AVP-923 for PBAM. 3/29/07 - Restructures to focus on AVP-923...
...plc (NASDAQ:JAZZ).O. 10/29/10 - FDA approves AVP-923 for PBA as NuedextaP. 6/25/13 - EC approves Nuedexta...
BioCentury | Dec 8, 2014
Company News

Avanir, Otsuka Pharmaceutical deal

...1, before the deal was announced. The deal is expected to close in 1Q15. Avanir’s AVP-923...
...has completed a Phase II trial to treat agitation in patients with Alzheimer’s disease (AD). AVP-923...
...treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Avanir markets the compound in a different dosage as Nuedexta...
BioCentury | Dec 3, 2014
Top Story

Otsuka buying Avanir for $3.5B

...to close in 1Q15. In September, Avanir's market cap nearly doubled to $2.1 billion after AVP-923...
...endpoint in a Phase II trial to treat agitation in patients with Alzheimer's disease (AD). AVP-923...
...see BioCentury Extra, Sept. 15) . Avanir markets the compound in a different dosage as Nuedexta...
BioCentury | Oct 20, 2014
Clinical News

Nuedexta dextromethorphan/quinidine: Additional Phase II data

...receive AVP-923 or placebo for an additional 5 weeks. Patients who initially received AVP-923 continued AVP-923...
...dose of dextromethorphan/quinidine (dosed once daily for 7 days followed by twice-daily maintenance dosing) as Nuedexta...
...PD-LID). Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Product: Nuedexta dextromethorphan/quinidine ( AVP-923 ) (formerly Neurodex...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...a market cap over $2 billion. The stock rose 85% on Sept. 12 on news AVP-923...
...in a Phase II trial. Avanir already markets a different dose of AVP-923 as Nuedexta dextromethorphan/quinidine...
BioCentury | Sep 25, 2014
Financial News

Avanir raises $200.2M follow-on

...to raise $200 million, after closing the day at $11.21. Earlier this month, Avanir's AVP-923 dextromethorphan/quinidine...
Items per page:
1 - 10 of 194